Vor Biopharma pivots to telitacicept for autoimmune diseases, backed by $491M cash to 2029. Click here to read an analysis of ...
Travere Therapeutics has transitioned into a rare disease commercial platform, driven by FILSPARI’s growth in IgAN and recent FSGS approval. More on TVTX stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results